Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies: Evidence for autoimmunity including neurologic and connective tissue diseases

Medicine

Volumn 84, Issue 4, 2005, Pages 208-217

  Davis III, John M ^a,b   Moder, Kevin G ^a   Homburger, Henry A ^a   Ytterberg, Steven R ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; CELECOXIB; CELL NUCLEUS ANTIGEN; ETANERCEPT; HYDROXYCHLOROQUINE; LA ANTIBODY; METHOTREXATE; PLASMA PROTEIN; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SCL 70 ANTIBODY; STEROID;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; ELECTRODIAGNOSIS; ELECTROMYOGRAPHY; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MYELOOPTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; SEROLOGY; SWEAT TEST; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ANTIBODIES, ANTINUCLEAR; ANTIGENS, NUCLEAR; AUTOIMMUNITY; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; SJOGREN'S SYNDROME;

EID: 22644443029     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.md.0000173181.87969.eb     Document Type: Article

References (42)

1. Andonopoulos AP, Lagos G, Drosos AA, Moutsopoulos HM. The spectrum of neurological involvement in Sjogren's syndrome. Br J Rheumatol. 1990;29:21-23.
2. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med. 2003;349: 1526-1533.
3. Earned S, Goodman AD, Mattson DH. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology. 1995;45:384-385.
4. Belfiore N, Rossi S, Bobbio-Pallavicini F, Epis O, Caporali R, Montecucco C. Anti-Ro(SS-A) 52 kDa and 60 kDa specificities in undifferentiated connective tissue disease. Joint Bone Spine. 2000;67: 183-187.
5. Benatar M. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1999;52:1520-1521.
6. Collard RC, Koehler RP, Mattson DH. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology. 1997;49: 857-861.
7. Danieli M, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, Pietrogrande M, Invernizzi F, Vanoli M, Scorza R, Sabbadini M, Gerli R, Corvetta A, Farina G, Salsano F, Priori R, Valesini G, Danieli G. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 1999;17:585-591.
8. de Andres C, Guillem A, Rodriguez-Mahou M, Lopez Longo FJ. Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients. Acta Neurol Scand. 2001;104:83-87.
9. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424-432.
10. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612-1618.
11. Font J, Valls J, Cervera R, Pou A, Ingelmo M, Graus F. Pure sensory neuropathy in patients with primary Sjogren's syndrome: clinical, immunological, and electromyographic findings. Ann Rheum Dis. 1990; 49:775-778.
12. Freddo L, Hays AP, Nickerson KG, Spatz L, McGinnis S, Lieberson R, Vedeler CA, Shy ME, Autilio-Gambetti L, Grauss FC, Petito F, Chess L, Latov N. Monoclonal anti-DNA IgM kappa in neuropathy binds to myelin and to a conformational epitope formed by phosphatidic acid and gangliosides. J Immunol. 1986;137:3821-3825.
13. Gibbs AN, Moroney J, Foley-Nolan D, O'Connell PG. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford). 2002;41:470-471.
14. Gold R, Linington C. Devic's disease: bridging the gap between laboratory and clinic. Brain. 2002;125(pt. 7):1425-1427.
15. Hart IK. Acquired neuromyotonia: a new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci. 2000;319:209-216.
16. Hayashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M, Kondo S, Maekawa S, Kumagai S. Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: comparison with immunofluorescence assay in 307 patients. Clin Chem. 2001;47:1649-1659.
17. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
18. Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem. 2002;48:2171-2176.
19. Homburger HA. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc. 1995;70:183-184.
20. Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med. 1998; 122:993-999.
21. Jaskowski TD, Schroder C, Martins TB, Mouritsen CL, Litwin CM, Hill HR. Screening for antinuclear antibodies by enzyme immunoassay. Am J Clin Pathol. 1996;105:468-473.
22. Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124:71-81.
23. Keren DF. Antinuclear antibody testing. Clin Lab Med. 2002;22: 447-474.
24. Lippa CF, Chad DA, Smith TW, Kaplan MH, Hammer K. Neuropathy associated with cryoglobulinemia. Muscle Nerve. 1986;9:626-631.
25. Lock RJ, Unsworth DJ. Antibodies to extractable nuclear antigens. Has technological drift affected clinical interpretation? J Clin Pathol. 2001; 54:187-190.
26. Lucchinetti CF, Handler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(pt 7):1450-1461.
27. Michielsens B, Walravens M, Vermylen J, Carton H. Diagnostic significance of antinuclear antibodies in neurologic patients. Acta Neurol Scand. 1991;84:102-106.
28. Moder KG. Immunologic tests in rheumatology. Ann Allergy Asthma Immunol. 1998;81:539-544, 547.
29. Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus. 1998;7:95-100.
30. Offen D, Halevi S, Orion D, Mosberg R, Stern-Goldberg H, Melamed E, Atlas D. Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology. 1998;51:1100-1103.
31. O'Hanlon GM, Veitch J, Gallardo E, Ilia I, Chancellor AM, Willison HJ. Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity. 2000; 32:133-144.
32. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology. 1997;49:1289-1292.
33. Reichlin M. ANA negative systemic lupus erythematosus sera revisited serologically. Lupus. 2000;9:116-119.
34. Reisner BS, DiBlasi J, Goel N. Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies. Am J Clin Pathol. 1999;111:503-506.
35. Sanchez-Guerrero J, Lew RA, Fossel AH, Schur PH. Utility of anti-Sm, anti-RNP, anti-Ro/SS-A, and anti-La/SS-B (extractable nuclear antigens) detected by enzyme-linked immunosorbent assay for the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 1996;39:1055-1061.
36. Simmons-O'Brien E, Chen S, Watson R, Antoni C, Petri M, Hochberg M, Stevens MB, Provost TT. One hundred anti-Ro (SS-A) antibody positive patients: a 10-year follow-up. Medicine (Baltimore). 1995;74: 109-130.
37. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47:434-444.
38. Spadaro M, Amendolea MA, Mazzucconi MG, Fantozzi R, Di Lello R, Zangari P, Masala G. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler. 1999;5:121-125.
39. Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, Schaller J, Talal N, Winchester R. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277.
40. Thomson K, Murphy A, Goodfield M, Misbah S. Is it useful to test for antibodies to extractable nuclear antigens in the presence of a negative antinuclear antibody on Hep-2 cells? J Clin Pathol. 2001;54:413.
41. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, Stievenart JL, Weill B, Lubetzki C, Lyon-Caen O. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55:517-521.
42. Vernino S, Auger RG, Emslie-Smith AM, Harper CM, Lennon VA. Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology. 1999;53:1233-1239.